ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

October 23, 2026 updated by: argenx

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a platform study and is governed by a single master protocol that enables multiple regimens to be evaluated in separate intervention-specific appendixes (ISAs).

The key design structure of the platform study comprises: common master protocol screening period, ISA-specific screening period, ISA treatment period of variable duration and design and ISA safety follow-up/follow-up period of variable duration.

Details on each study period will be specified in the ISAs. Following ISAs are included in this platform study:

  • NCT07284420 - ADAPT Forward 1 - a study to evaluate empasiprubart IV as add-on therapy to efgartigimod IV in participants with AChR-Ab seropositive generalized myasthenia gravis with a partial clinical response to efgartigimod (https://www.clinicaltrials.gov/study/NCT07284420)
  • NCT07673627 - Adapt Forward 2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis (https://clinicaltrials.gov/study/NCT07673627)

More information can be found here: https://clinicaltrials.argenx.com/adaptforward

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Belgium
      • Leuven, Belgium, 3000
      • Liège, Belgium, 4000
  • Germany
      • Berlin, Germany, 13353
        • Recruiting
        • Charité - Universitätsmedizin Berlin
        • Contact:
      • Göttingen, Germany, 37075
      • Würzburg, Germany, 97080
        • Recruiting
        • Universitätsklinikum Würzburg
        • Contact:
  • Greece
      • Athens, Greece, 115 28
      • Thessaloniki, Greece, 546 36
        • Recruiting
        • AHEPA University General Hospital of Thessaloniki
        • Contact:
  • Italy
    • Lombardy
      • Bergamo, Lombardy, Italy, 24127
        • Recruiting
        • ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII
        • Contact:
      • Milan, Lombardy, Italy, 20133
        • Recruiting
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
        • Contact:
  • Japan
      • Hanamaki, Japan, 025-0075
        • Recruiting
        • General Hanamaki Hospital - Kajomachi
        • Contact:
      • Narita, Japan, 286-8520
        • Recruiting
        • IUHW Narita Hospital
        • Contact:
    • Ibaraki
      • Tsukuba, Ibaraki, Japan, 305-8576
        • Recruiting
        • University of Tsukuba Hospital
        • Contact:
    • Kanagawa
      • Kawasaki-Shi, Kanagawa, Japan, 216-8511
        • Recruiting
        • St. Marianna University Hospital
        • Contact:
    • Miyagi
      • Sendai, Miyagi, Japan, 983-0045
        • Recruiting
        • National Hospital Organization Sendai Medical Center
        • Contact:
  • Poland
      • Warsaw, Poland, 00-665
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland, 85-065
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Poland, 31-505
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Poland, 40-689
  • Spain
      • Barcelona, Spain, 8041
        • Recruiting
        • Hospital de La Santa Creu i Sant Pau
        • Contact:
    • Malaga
      • Málaga, Malaga, Spain, 340120
        • Recruiting
        • Hospital Regional Universitario de Malaga - Hospital General
        • Contact:
  • United States
    • California
      • Carlsbad, California, United States, 92011
        • Recruiting
        • Profound Research LLC - Carlsbad
        • Contact:
    • Florida
      • Miami, Florida, United States, 33180
        • Recruiting
        • Visionary Investigators Network
        • Contact:
      • Miami, Florida, United States, 33133
        • Recruiting
        • Visionary Investigators Network
        • Contact:
      • Tampa, Florida, United States, 33620
        • Recruiting
        • University of South Florida
        • Contact:
          • Tuan Vu, MD
          • Phone Number: (813) 974-9413
          • Email: tvu6@usf.edu
    • Massachusetts
      • Boston, Massachusetts, United States, 02114-2621
        • Recruiting
        • Massachusetts General Hospital
        • Contact:
    • Michigan
      • Detroit, Michigan, United States, 48202-2608
        • Recruiting
        • Henry Ford Health System
        • Contact:
    • Nevada
      • Las Vegas, Nevada, United States, 89106
        • Recruiting
        • Profound Research LLC at Las Vegas Neurology Center
        • Contact:
    • New York
      • Amherst, New York, United States, 14226
        • Recruiting
        • Dent Neurologic Institute - Amherst
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514-4221
        • Recruiting
        • University of North Carolina at Chapel Hill-170 Manning Dr.
        • Contact:
      • Durham, North Carolina, United States, 27710-0001
        • Recruiting
        • Duke Early Phase Clinical Research Unit - PPDS
        • Contact:
    • Ohio
      • Cincinnati, Ohio, United States, 45219=2364
        • Recruiting
        • University of Cincinnati Medical Center - Goodman St
        • Contact:
      • Columbus, Ohio, United States, 43221-3502
        • Recruiting
        • Ohio State Martha Morehouse Outpatient Care
        • Contact:
    • Tennessee
      • Chattanooga, Tennessee, United States, 37403-2136
    • Texas
      • Austin, Texas, United States, 78759
        • Recruiting
        • National Neuromuscular Research Institute
        • Contact:
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • University of Texas- San Antonio - Health Science Center - PPDS
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Description

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies
  • Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
  • If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening

Exclusion Criteria:

  • Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
  • Is MGFA (Myasthenia Gravis Foundation of America) Class V

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
ISA1 participants

Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Biological: Empasiprubart IV

Intravenous infusion of empasiprubart

Biological: Efgartigimod IV

Intravenous infusion of efgartigimod
ISA2 participants

Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Biological: Empasiprubart IV

Intravenous infusion of empasiprubart

Other: Placebo IV

Intravenous infusion of placebo

Biological: Efgartigimod PH20 SC PFS

Subcutaneous administration of Efgartigimod PH20 via pre-filled syringe (PFS)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes
Time Frame: Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)
Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
To evaluate the efficacy of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes
Time Frame: Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Each ISA record will specify the correct scale and time point
Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
argenx

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 19, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 7, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 7, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 8, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 8, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 19, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 26, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 23, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ARGX-999-2-MG-2000

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings